Financial Performance - The company's operating revenue for 2024 was CNY 911.37 million, a decrease of 3.44% compared to 2023[21]. - Net profit attributable to shareholders for 2024 was CNY 136.26 million, down 29.66% year-over-year[21]. - The net cash flow from operating activities decreased by 95.96%, amounting to CNY 8.14 million in 2024[24]. - Basic and diluted earnings per share for 2024 were CNY 1.11, reflecting a decline of 29.70% from the previous year[22]. - The weighted average return on equity decreased by 2.20 percentage points to 4.69% in 2024[22]. - The company's gross margin for the main business was 63.63%[163]. - The revenue from the machine vision segment was approximately CNY 909.71 million, a decrease of 3.43% compared to the previous year, with a gross margin of 63.63%[166]. - The sales revenue from core components of machine vision was about CNY 793.46 million, down 1.93% year-on-year, with a gross margin of 65.08%[166]. - The company reported a total revenue of 28,005.0 million RMB for the current period, compared to 21,695.9 million RMB in the previous period, indicating a growth of approximately 29.5%[134]. Dividend Distribution - The company plans to distribute a cash dividend of 2.50 RMB per 10 shares, totaling 30,473,172.00 RMB (including tax) for the fiscal year 2024, which represents 34.03% of the net profit attributable to shareholders[5]. - The profit distribution plan has been approved by the board and will be submitted to the shareholders' meeting for review[6]. - The company has already distributed a mid-term cash dividend of 15,890,609.15 RMB, leading to a total cash dividend of 46,363,781.15 RMB for the year[5]. Research and Development - Research and development expenses accounted for 23.81% of operating revenue, an increase of 2.38 percentage points compared to 2023[22]. - The company achieved a R&D investment of 216.96 million yuan, representing a year-on-year increase of 7.28%[109]. - The total R&D investment for the year was approximately ¥216.96 million, representing a 7.28% increase from the previous year, with R&D expenses accounting for 23.81% of operating revenue, up 2.38 percentage points[128][129]. - The number of R&D personnel increased to 1,034, up from 899, representing a growth rate of approximately 15%[136]. - The R&D team consists of 1,034 personnel, accounting for 39.50% of the total workforce, with expertise in optics, industrial design, and computer science[139]. - The company obtained 33 new invention patents, 57 utility model patents, and 10 design patents during the reporting period, bringing the total to 130 invention patents and 469 utility model patents[125][126]. Market and Industry Trends - The machine vision market in China reached a scale of 18.512 billion yuan in 2023, with a year-on-year growth of 8.49%, and is projected to exceed 39.5 billion yuan by 2028, indicating significant growth potential[80]. - The Chinese machine vision market is projected to grow to CNY 39.5 billion by 2028, indicating significant growth potential[192]. - The company anticipates continued growth in the machine vision sector, driven by rising demand in downstream industries such as 3C electronics and automotive[192]. - The company is focusing on diversifying its market strategy, particularly in the 3C electronics and lithium battery sectors, while also exploring opportunities in the automotive and semiconductor industries[194]. Risk Management - The company has detailed various risks and countermeasures in the report, particularly in the section on "Risk Factors"[3]. - The company faces risks related to technological obsolescence and core technology leakage, which could impact its competitive position[146][147]. - The company faces risks related to talent retention, management capabilities, and market competition as the industry matures[150][153]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The company has not faced any situations where more than half of the directors could not guarantee the authenticity, accuracy, and completeness of the annual report[12]. - The company has not reported any special arrangements for corporate governance[9]. Product Development and Innovation - The company has developed a comprehensive machine vision product line, including visual algorithms, industrial AI, and various sensors, to meet full-process visual needs of clients[40]. - The company plans to enhance its product line and expand its automation core component layout, focusing on R&D investments to strengthen its competitive edge[39]. - The company is focusing on the development of advanced algorithms for defect detection and object recognition, utilizing deep learning technologies[134]. - The company aims to upgrade its existing visual processing software and develop new modules for 3D reconstruction and industrial AI algorithms[198]. - The company plans to develop specialized medical code readers and embedded code readers to adapt to a wider range of applications, enhancing overall solution reliability[114]. Human Resources - As of December 31, 2024, the company employed 2,618 people, an increase of 350 from 2023, reflecting ongoing investment in human resources despite profit pressures[37]. - The total compensation for R&D personnel reached 15,765.87 million RMB, an increase from 14,699.43 million RMB, reflecting a rise of about 7.2%[136]. - The average salary for R&D personnel decreased to 15.25 million RMB from 16.35 million RMB, a decline of approximately 6.7%[136]. Financial Position - Cash and cash equivalents decreased by 63.64% to CNY 237.75 million, primarily due to reduced collections and increased supply chain payments[185]. - Accounts receivable at the end of the reporting period amounted to 73,412.91 million RMB, accounting for 23.04% of total assets, indicating a high risk of bad debts[155]. - Inventory at the end of the reporting period was valued at 14,435.02 million RMB, representing 4.53% of total assets, posing a risk of inventory write-downs[156]. - Fixed assets rose by 95.73% to CNY 527.80 million, attributed to the transfer of construction in progress for the new Suzhou factory to fixed assets[185]. Strategic Goals - The company aims for a revenue growth rate of no less than 20% for 2025, based on the 2024 revenue as a benchmark[61]. - The company plans to enhance market expansion and product delivery capabilities to improve operational efficiency and profitability[61]. - The company will continue to invest in talent acquisition and development, particularly in technical and management roles, to support its growth strategy[200].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 267,728,001.48, representing an increase of 18.09% compared to CNY 226,715,956.09 in the same period last year[3] - The net profit attributable to shareholders was CNY 57,857,653.98, showing a slight increase of 0.97% from CNY 57,301,927.62 year-on-year[3] - The net profit after deducting non-recurring gains and losses was CNY 54,489,549.52, which is an increase of 11.40% compared to CNY 48,913,509.40 in the previous year[3] - Total operating revenue for Q1 2025 reached ¥267.73 million, a 18.1% increase from ¥226.72 million in Q1 2024[15] - Net profit for Q1 2025 was ¥57.86 million, slightly up from ¥57.30 million in Q1 2024, representing a 1.0% increase[16] - Operating profit for Q1 2025 was ¥68,041,471.32, slightly down from ¥69,541,044.25 in Q1 2024, reflecting a decrease of 2.2%[25] - Net profit for Q1 2025 was ¥65,125,311.65, compared to ¥65,848,564.70 in Q1 2024, indicating a decrease of 1.1%[25] Cash Flow - The net cash flow from operating activities improved significantly to CNY 2,326,086.24, compared to a negative cash flow of CNY -2,923,255.42 in the same period last year[3] - Cash flow from operating activities for Q1 2025 was ¥2.33 million, a significant improvement from a negative cash flow of ¥2.92 million in Q1 2024[18] - Cash flow from operating activities showed a net outflow of ¥9,598,696.99 in Q1 2025, an improvement from a net outflow of ¥15,973,451.97 in Q1 2024[27] - Investment activities generated a net cash inflow of ¥73.52 million in Q1 2025, compared to ¥150.77 million in Q1 2024[19] - Cash inflow from investment activities was ¥289,116,054.31 in Q1 2025, compared to ¥212,000,000.00 in Q1 2024, marking a significant increase[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,260,618,414.34, reflecting a growth of 2.33% from CNY 3,186,261,629.27 at the end of the previous year[4] - The total liabilities as of March 31, 2025, were RMB 311,080,357.92, up from RMB 269,289,560.10, indicating an increase of approximately 15.5%[13] - The total assets of the company amounted to ¥3,308,829,888.55, a slight decrease from ¥3,231,222,175.57 in the previous period[23] - The total liabilities increased to ¥280,500,877.89 from ¥242,900,591.23, representing an increase of 15.5%[23] Shareholder Information - The company reported a total of 6,917 common shareholders at the end of the reporting period[8] - The equity attributable to shareholders increased to CNY 2,949,538,056.42, up by 1.12% from CNY 2,916,972,069.17 at the end of the previous year[4] - The total equity attributable to the parent company was RMB 2,949,538,056.42, an increase from RMB 2,916,972,069.17, reflecting a growth of approximately 1.1%[13] - The total equity of the company rose to ¥3,028,329,010.66 from ¥2,988,321,584.34, showing an increase of 1.3%[23] Research and Development - Research and development expenses totaled CNY 51,238,406.46, which is an increase of 5.48% from CNY 48,577,247.64 year-on-year[3] - The ratio of R&D expenses to operating revenue was 19.14%, down from 21.43% in the previous year, indicating a decrease of 2.29 percentage points[4] - Research and development expenses for Q1 2025 were ¥51.24 million, up from ¥48.58 million in Q1 2024, indicating a 5.4% increase[15] - Research and development expenses for Q1 2025 were ¥49,496,505.70, up from ¥46,677,246.80 in Q1 2024, reflecting a growth of 3.5%[25] Inventory and Receivables - The company's inventory increased to RMB 176,565,373.25 from RMB 144,350,183.89, which is an increase of approximately 22.3%[11] - The accounts receivable stood at RMB 735,130,457.68, slightly up from RMB 734,129,103.69, showing a marginal increase of about 0.14%[11] - The company's inventory increased to ¥172,174,618.54 from ¥141,762,998.99, indicating a rise of 21.5%[22] Other Financial Metrics - The weighted average return on net assets was 1.96%, slightly down from 1.97% in the previous year[3] - Basic and diluted earnings per share for Q1 2025 were both ¥0.4752, compared to ¥0.4688 in Q1 2024, reflecting a 0.9% increase[16] - The company experienced a decrease in other comprehensive income, reporting a net loss of ¥173,781.40 in Q1 2025 compared to a gain of ¥226,372.42 in Q1 2024[16] Financial Obligations - The company reported a decrease in short-term borrowings, with no specific amount listed, indicating a potential reduction in leverage[13] - Cash paid for debt repayment was $29,820,000.00, indicating ongoing financial obligations[28]

广东奥普特科技股份有限公司 审计报告 天 职 业 字 [2025] 19439 号 目 录 审计报告 -- -1 2024 年度财务报表 -- -7 2024 年度财务报表附注 -- -19 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查 审计报告 天职业字[2025]19439 号 广东奥普特科技股份有限公司全体股东: 一、审计意见 我们审计了广东奥普特科技股份有限公司(以下简称"奥普特")财务报表,包括 2024 年 12 月 31 日的合并及母公司资产负债表,2024 年度的合并及母公司利润表、合并及母公 司现金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 奥普特 2024 年 12月 31 日的合并及母公司财务状况以及 2024年度的合并及母公司经营成果 和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业 ...

广东奥普特科技股份有限公司 二、注册会计师的责任 募 集 资 金 存 放 与 实 际 使 用 情 况 鉴 证 报 告 天 职 业 字 [2025]19439-1 号 目 募集资金存放与实际使用情况鉴证报告 -- -1 关于公司募集资金存放与实际使用情况的专项报告 -- -3 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.or.jsyx.cn）"进行整理 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.cn.t.px?btltypt.cn）" 报告编码：京208026288 募集资金存放与实际使用情况鉴证报告 天职业字[2025]19439-1 号 广东奥普特科技股份有限公司全体股东: 我们审核了后附的广东奥普特科技股份有限公司(以下简称"奥普特")《关于公司募 集资金存放与实际使用情况的专项报告》。 一、管理层的责任 奥普特管理层的责任是按照中国证监会《上市公司监管指引第 2 号 --- 上市公司募集资 金管理和使用的监管要求》、上海证券交易所颁布的《上海证券交易所科创板上市公司自律 监管指引第 1 号 --- 规范运作》及相关格式指引规定编制《 ...

广东奥普特科技股份有限公司 .您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mc.gov.cn） 进行查询 . 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 进行管理 内部控制审计报告 天职业字[2025]19439-2 号 广东奥普特科技股份有限公司全体股东: 内 部 控 制 审 计 报 告 天职业字[2025]19439-2 号 目 录 内部控制审计报告— -1 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了广 东奥普特科技股份有限公司(以下简称"奥普特")2024年12月 31 日的财务报告内部控制 的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定,建立健全和有效实施内部控制,并评价其有效性是奥普特董事会的责任。 二、注册会计师的责任 t we 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 内部控制审计报告(续) 三、内部控制 ...

国信证券股份有限公司 关于广东奥普特科技股份有限公司 2024 年度募集资金存放与实际使用情况的核查意见 国信证券股份有限公司（以下简称"保荐机构"）作为广东奥普特科技股份 有限公司（以下简称"奥普特""公司"）首次公开发行股票并在科创板上市的 保荐机构，履行持续督导职责，根据《证券发行上市保荐业务管理办法》《上市 公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海证券 交易所科创板上市公司自律监管指引第1号——规范运作》《上海证券交易所科 创板股票上市规则》等有关规定，对奥普特2024年度募集资金的存放和使用情况 进行了核查，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 根据中国证券监督管理委员会《关于同意广东奥普特科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2020〕3176号），公司首次公开发行人 民币普通股（A股）2,062.00万股，募集资金总额为人民币161,846.38万元，扣除 发行费用（不含增值税）8,249.48万元后，募集资金净额为153,596.90万元。本次 发行募集资金已于2020年12月28日全部到位，天职国际会计师事务 ...

Financial Performance - The company reported a basic earnings per share of 0.4752 yuan for Q1 2025, representing a 1.37% increase compared to 0.4688 yuan in Q1 2024 [1] - The total revenue for Q1 2025 was 2.68 billion yuan, an 18.06% increase from 2.27 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was 0.58 billion yuan, showing a 1.75% increase from 0.57 billion yuan in Q1 2024 [1] - The return on equity (ROE) for Q1 2025 was 1.96%, slightly down from 1.97% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 94.495 million shares, accounting for 77.32% of the circulating shares, with a decrease of 0.6336 million shares compared to the previous period [1] - Major shareholders include Lu Zhilin with 36.4856 million shares (29.85%) and Lu Shenglin with 35.6874 million shares (29.20%), both remaining unchanged [2] - New entrants among the top shareholders include the Fortune Tianhui Growth Mixed Fund with 1.5 million shares (1.23%) and the Fortune Value Advantage Mixed A with 0.7956 million shares (0.65%) [2] Dividend Policy - The company has decided not to distribute dividends or transfer shares in this reporting period [3]

证券代码：688686 证券简称：奥普特 公告编号：2025-020 广东奥普特科技股份有限公司 关于参加 2024 年度科创板人工智能及软件行业集体 业绩说明会暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 29 日（星期二）15:00-17:00 会议召开地点： 上海证券 交易所上证路演中心（ 网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 22 日（星期二）至 4 月 28 日（星期一）16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@optmv.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 广东奥普特科技股份有限公司（以下简称"公司"）将于 2025 年 4 月 29 日 发布公司 2024 年年度报告及 2025 年第一季度报告，为便于广大投资者更全面深 入地了解公司 202 ...

好的 尊敬的各位投资者大家早上好我是中泰机械的王可今天由我和我们团队的成员秦博洋为大家汇报我们关于奥普特的一个最新的深度报告那首先我将会花大概五分钟左右的时间把公司的核心观点跟各位领导做一个汇报接下来博洋会在金门海军上直接以线上PPT的形式给大家再做一个深度的讲解奥普特这个公司的主业是做机械试学当中的一个核心零部件 但是在检测环节过去其实像产业的头目公司其实主要还是以人力检测为主这是因为传统的检测算法没有办法匹配这样的一个质检的要求为什么呢你以苹果为例它的如果用传统的机器视觉的算法去做质检的话那么这个算法肯定是在小批量生产的过程当中就要开发出来那么传统的算法是先录入缺陷然后去匹配这个缺陷如果发现匹配了那就是有缺陷 但是小批量量产当中录入的缺陷的样本量是不够的在大批量生产的时候会出现新的缺陷这就导致传统的算法它不够智能不够全面它可能会出现错点和漏点所以最终苹果采用的方法还是以 那么当年是靠核心文件当中的光源上市的此后拓展到了相机和镜头那么后续也逐步的拓展到的软件也就是整个成套的方案从硬到软都能够做看完去讲这个公司在过去两年的时间由于业绩的低于期股价其实是一直在下跌的包括资本市场的关注也并不高原因主要来自于它的主 ...

规模方面，科创100指数ETF近1年规模增长3.71亿元，实现显著增长，新增规模位居可比基金2/10。 份额方面，科创100指数ETF近2周份额增长1.14亿份，实现显著增长，新增份额位居可比基金2/10。 资金流入方面，科创100指数ETF近4个交易日内有3日资金净流入，合计"吸金"6572.26万元，日均净流入达1643.06万元。 数据显示，杠杆资金持续布局中。科创100指数ETF前一交易日融资净买额达403.64万元，最新融资余额达3.32亿元。 截至2025年4月10日 10:10，上证科创板100指数(000698)强势上涨4.56%，成分股生益电子(688183)上涨13.18%，华曙高科(688433)上涨12.94%，道通科技 (688208)上涨12.70%，铂力特(688333)，奥普特(688686)等个股跟涨。科创100指数ETF(588030)上涨4.37%， 冲击3连涨。最新价报0.93元。拉长时间看，截 至2025年4月9日，科创100指数ETF近3月累计上涨4.44%。 流动性方面，科创100指数ETF盘中换手3.81%，成交2.29亿元。拉长时间看，截至4月9日，科创100 ...